SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry ($BB.TSX) is trending as investors anticipate upcoming earnings, with community members expressing optimism about QNX technology and its role in automotive and IoT sectors. Bullish sentiment is fueled by technical indicators, such as golden crosses and wedge formations, suggesting a potential breakout. Discussions also focus on future revenue and profitability, with some highlighting the company's strategic partnerships and potential for growth.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

LABU is trending as traders discuss the potential for a biotech sector rally, fueled by optimism around AI-driven drug discovery and development. Community members are actively trading LABU calls, citing technical indicators and potential market shifts from crypto and big tech into US small caps. Several news articles are circulating highlighting advancements in AI applications within the pharmaceutical and healthcare industries, further contributing to the bullish sentiment.

Anheuser-Busch InBev SA/NV operates as a holding company, which engages in the manufacture and distribution of alcoholic and non-alcoholic beverages. It operates through the following geographical segments: North America, Middle Americas, South America, EMEA, Asia Pacific, and Global Export and Holding Companies. The company was founded on August 2, 1977 and is headquartered in Leuven, Belgium.

Anheuser-Busch InBev SA/NV - ADR

Anheuser-Busch InBev

Anheuser-Busch InBev (BUD) is trending amid discussions around market share, brand perception, and a recent acquisition of BeatBox Beverages. Community members debate the company's long-term strategy, with some citing concerns around market share and previous marketing decisions, while others point to positive momentum from digital channels and expansion into new beverage categories. Broader market conditions and potential impacts from changing consumer preferences are also being considered.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

The launch of the Bitwise XRP ETF, trading under the ticker TOXR, is driving much of the current conversation around XRP. Community members are debating the potential impact of the new ETF on XRP's price, analyzing technical charts, and discussing entry points. Some are optimistic about institutional adoption and a potential Christmas rally, while others express concerns about trading volume and regulatory hurdles.

Decentraland

Decentraland's MANA is trending as gaming tokens gain momentum, with community members actively discussing potential metaverse news and price predictions. The recent price action and strong volume have reignited interest, with some speculating about a run to previous all-time highs. There is optimism surrounding the broader gaming and metaverse sector, with some comparing MANA's potential to that of other cryptocurrencies that have experienced significant growth after ETF developments.

Tyson Foods, Inc. engages in the processing of prepared food and other related products. It operates through the following segments: Beef, Pork, Chicken, and Prepared Foods. The Beef segment includes processing live fed cattle and fabricating dressed beef carcasses into primal and sub-primal meat cuts and case-ready products. The Pork segment focuses on live market hogs and fabricating pork carcasses. The Chicken segment is involved in raising and processing live chickens into fresh, frozen, and value-added chicken products, and sales from specialty products. The Prepared Foods segment manufactures and markets food products and offers logistic operations to move products through the supply chain. The company was founded by John W. Tyson in 1935 and is headquartered in Springdale, AR.

Tyson Foods, Inc. - Ordinary Shares - Class A

Tyson Foods, Inc.

Tyson Foods ($TSN) is trending as community members discuss options activity and potential upside, with some citing a cup and handle formation and increased price targets. Recent actionable trade alerts highlight bullish sentiment based on moving averages, while others point to overbought conditions and potential pullbacks. The company's recent earnings report and capacity adjustments in beef processing are also driving conversation.

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals is trending due to a surge in bullish sentiment and strong breakout momentum, with high insider ownership fueling speculation of "smart money" involvement. Community discussions revolve around insider buying, share counts, and the potential for a phase III cancer trial. Some investors express concern about management while others anticipate further gains.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending amid community discussion about its price action and potential for future growth, with some expressing concern over its performance compared to other cryptocurrencies.  A key point of discussion is its underlying technology and real-world enterprise applications, with comparisons being drawn to emerging competitors.  Some community members are focused on accumulating more HBAR, anticipating a significant price increase in the long term.

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Immunome Inc

IMNM is trending as investors digest news of upcoming Phase 3 data and recent business development activities, including acquisitions to bolster their antibody-drug conjugate capabilities. Community discussion revolves around the potential for a squeeze, with some expressing concern over the company's cash runway and others highlighting insider buying. The stock's volatility and upcoming data readouts are key points of interest for traders.

Loopring is a Decentralized Exchange (DEX) built on an Ethereum Layer-2 (L2) solution called zkRollup. It has both Automated Market Maker (AMM)-based and orderbook-based exchanges.   zkRollup is an Ethereum L2 scaling solution that migrates computations off the blockchain. Loopring protocol only uses the underlying Ethereum blockchain as a data layer and a verification layer. As a result, Loopring's throughput is as high as 2,025 trades per second compared to Ethereum’s current throughput of 15 transactions per second. The result is that the cost per trade settlement is as small as $0.00015.  Loopring's performance is sufficient for professional traders and market makers to deploy algorithmic strategies and other automated trading bots. This was not previously possible on any DEX as it was prohibitively slow and expensive. By building on top of Loopring 3.0, orderbook-based DEXs can be commercially viable for the first time. Loopring expects non-custodial exchanges can begin to outcompete and displace many centralized counterparts.

Loopring

Loopring is trending as traders discuss its potential for a short squeeze and speculate on upcoming price movements, with some community members pointing to bullish chart patterns. AI news surrounding $PROMPT and $NVDA may be contributing to the upward momentum. The coin's historical connection to GameStop and current state as a Layer 2 project are also part of the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jefferies🏁 $MPLT Buy/$32 
KRTX - $BMY CERE - $ABBV      $NBIX 
Jefferies said in its initiation—MPLT has an intriguing Phase II pipeline that could ultimately disrupt the CNS/neuro landscape, starting with ML-007C-MA (oral M1/M4 agonist) in schizophrenia (SCZ) and Alzheimer&#39;s disease psychosis (ADP). Second asset ML-004 is an oral 5-HT1B/1D for autism spectrum disorder (ASD). 
 
Each program represents a $1B+ blockbuster 
opportunity, and all of them will have pbo-controlled Phase II data in 2026-27 (3 shots on goal). 
 
As such, we like the risk/reward at $660M cap, since $1B+ in peak sales (conservative) x low 2-3x multiple = $2-3B of value per program (unadjusted), which could be quickly realized over the next 1-2 years. 
 
Also, ML-007&#39;s program success could attract Big Pharma attention. Muscarinics in SCZ alone have 
been a high-value target, as evidenced by two major M&amp;A deals with $14B+ for BMY/KRTX (Cobenfy) and $9B for ABBV/CERE (emracladiine).

MapLight Therapeutics&#39; ( $MPLT ) IPO is Reportedly Well Oversubscribed, Ahead of its Scheduled Pricing on October 26 - Yesterday, As Per Bloomberg/BBG. 
$KRTX - $BMY 
https://www.sec.gov/Archives/edgar/data/1770069/000119312525231829/d90027ds1a.htm 
The current offering is 14.75 million shares at $17 each to raise $250.8 million. The company is expected to stop taking orders Thursday after markets close in New York; the offering is scheduled to price on October 26, according to a management presentation. 
 
Morgan Stanley, Jefferies Financial Group Inc., Leerink Partners, and Stifel Financial Corp. are working on the offering. 
 
MapLight is pioneering the discovery, development, and delivery of transformative treatments for brain disorders:

exceptions and regulatory safe harbors available, and the range of interpretations to which they are subject, it is possible that some of our current or future practices might be challenged under one or more of these laws.

StockTwits Web

Karuna Therapeutics Inc

Bristol-Myers Squibb Co.

Quantumup

Jefferies reiterated $MPLT Buy/$32 
KRTX - $BMY    CERE - $ABBV     $NBIX 
Jefferies said in its note to investors: 
In H2:26, we think oral ML-007C-MA (novel M1/M4 muscarinic) has a 30-40% PoS to generate superior Phase II schizophrenia data (pot&#39;l +100% stock move), helping de-risk the second program in Alzheimer&#39;s psychosis, which has Phase II data in H2:27 (another pot&#39;l +100% move). 
 
Approved in SCZ, BMY&#39;s Cobenfy (M1/M4) is delaying its Phase III ADP readout (ADEPT-2) to YE:26 (likely after MPLT&#39;s SCZ data), allowing &#39;007 to first prove whether it is superior in SCZ.

MapLight Therapeutics Inc.

Abbvie Inc

Neurocrine Biosciences, Inc.

 
Jefferies said in its initiation—MPLT has an intriguing Phase II pipeline that could ultimately disrupt the CNS/neuro landscape, starting with ML-007C-MA (oral M1/M4 agonist) in schizophrenia (SCZ) and Alzheimer's disease psychosis (ADP). Second asset ML-004 is an oral 5-HT1B/1D for autism spectrum disorder (ASD). 
 
Each program represents a $1B+ blockbuster 
opportunity, and all of them will have pbo-controlled Phase II data in 2026-27 (3 shots on goal). 
 
As such, we like the risk/reward at $660M cap, since $1B+ in peak sales (conservative) x low 2-3x multiple = $2-3B of value per program (unadjusted), which could be quickly realized over the next 1-2 years. 
 
Also, ML-007's program success could attract Big Pharma attention. Muscarinics in SCZ alone have 
been a high-value target, as evidenced by two major M&A deals with $14B+ for BMY/KRTX (Cobenfy) and $9B for ABBV/CERE (emracladiine).